SOLVHealthcare · Medical Instruments & SuppliesThe 15 Wall Street analysts covering Solventum Corp. hold a median 12-month price target of $95 — +3.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 3 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Solventum Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (98): The share count has been shrinking and the company is not leaning on new borrowing.
Accruals (53): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SOLV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +3.6% from it.
Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Aug 2026 | BTIG | Maintains | Buy | $91 → $95 |
| 6 Aug 2026 | Keybanc | Maintains | Overweight | $93 → $102 |
| 6 Aug 2026 | Piper Sandler | Maintains | Overweight | $92 → $105 |
| 6 Aug 2026 | Stifel | Maintains | Buy | $90 → $100 |
| 6 Aug 2026 | UBS | Maintains | Buy | $95 → $101 |
| 6 Aug 2026 | Wedbush | Maintains | Outperform | $94 → $101 |
| 28 July 2026 | UBS | Upgrade | Buy | $95 |
| 28 July 2026 | UBS | Upgrade | Buy | — |
| 9 July 2026 | BMO Capital | Initiates | Market Perform | — |
| 15 May 2026 | Wedbush | Initiates | Outperform | — |
| 6 May 2026 | BTIG | Reiterates | Buy | — |
| 6 May 2026 | Keybanc | Maintains | Overweight | — |
| 6 May 2026 | Stifel | Maintains | Buy | — |
| 6 May 2026 | UBS | Maintains | Neutral | — |
| 6 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 27 Apr 2026 | Keybanc | Maintains | Overweight | — |
| 17 Apr 2026 | Piper Sandler | Maintains | Overweight | — |
| 24 Mar 2026 | Rothschild & Co | Initiates | Sell | — |
| 27 Feb 2026 | BTIG | Reiterates | Buy | — |
| 27 Feb 2026 | Keybanc | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SOLV appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Sept 2026, Solventum Corp. returned +26.7% against +20.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 56% of US stocks
Cheaper than 55% of US stocks
Cheaper than 32% of US stocks
Cheaper than 18% of US stocks
Higher than 32% of US stocks
Higher than 39% of US stocks
Higher than 72% of US stocks
Higher than 64% of US stocks
Higher than 80% of US stocks
Higher than 89% of US stocks
Higher than 63% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Solventum Corp. has a market value of $15.6B and an enterprise value of $20.4B.
Revenue in the twelve months to 30 June 2026: $8.3B. The latest quarter grew 2.2% year on year.
Net income over the same four quarters: $1.4B, a 17.3% net margin.
Diluted earnings per share, trailing twelve months: $8.18.
Free cash flow in the twelve months to 30 June 2026: −$118.0M.
Trailing P/E: 11.2×; forward P/E: 12.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Solventum Corp. employs 20,584 people — $404K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Solventum Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Solventum (SOLV) reported earnings 30 days ago, and its stock has risen 11.4% since that report. The article examines what may lie ahead for the company following this gain.
Why it matters — SOLV watchers would care because the article assesses the stock's post-earnings momentum and potential trajectory after an 11.4% increase.
Solventum announced that members of its management team will participate in a fireside chat at the 2026 Wells Fargo Healthcare Conference, scheduled for Wednesday, September (date). The announcement was made via PRNewswire from Eagan, Minnesota.
Why it matters — A SOLV watcher would care because the company's management will be speaking publicly at a major healthcare industry conference, offering exposure and a venue for discussion about the company.
Zacks Investment Research reports that Solventum's growth, higher earnings outlook, and cost cuts strengthen its investment case, though heavy debt and margin risks projected for 2027 temper the upside. The piece weighs both the company's improving fundamentals against persistent financial concerns.
Why it matters — SOLV watchers would care because the analysis highlights the balance between the company's improved growth and earnings momentum and the lingering debt and margin challenges that could affect its financial position.
Zacks Investment Research highlights Solventum (SOLV) as a stock to watch, citing its earnings growth and price strength and featuring it on the Zacks Focus List for market-beating candidates.
Why it matters — Solventum watchers may find this notable because the stock is being flagged for its performance and inclusion in a curated list of potentially strong performers.
Zacks Investment Research highlighted Solventum (SOLV) as a top value stock for the long term, referencing the Zacks Style Scores framework for identifying strong, market-beating stocks for investment portfolios.
Why it matters — The item flags SOLV as a value stock with long-term potential in a stock-selection framework, which a Solventum watcher would note as a positive signal.
The 15 Wall Street analysts covering Solventum Corp. have a median 12-month price target of $95, with estimates ranging from $70 to $113. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 15 analysts covering Solventum Corp., 8 rate it a Buy, 5 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Solventum Corp. 91 out of 100 across roughly 4,600 US stocks as at 3 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Sept 2026, Solventum Corp. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (98 of 100).
No one can know that. What the data says: the median 12-month target from 15 analysts implies +3.6% from the last close, and Ticker Nerd's factor model ranks Solventum Corp. 91 out of 100 as at 3 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Solventum Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SOLV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $70 to $113 over the next 12 months.
Solventum Corp. returned +26.7% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Solventum Corporation is a healthcare company that develops and commercializes a broad portfolio of products and software designed to address clinical and operational needs across care settings. Its Medsurg business provides wound care, skin care, I.V.
The most recent item we track (Zacks Investment Research, 4 Sept 2026): "Solventum (SOLV) Up 11.4% Since Last Earnings Report: Can It Continue?". Solventum (SOLV) reported earnings 30 days ago, and its stock has risen 11.4% since that report. The article examines what may lie ahead for the company following this gain.
Solventum Corporation is a healthcare company that develops and commercializes a broad portfolio of products and software designed to address clinical and operational needs across care settings. Its Medsurg business provides wound care, skin care, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, and medical electrodes. The Dental Solutions segment offers products used in restorative and orthodontic workflows, including brackets, aligners, cements, and bonding agents. Through Health Information Systems, Solventum supplies software and services that support physician documentation, coding automation, speech recognition, and data visualization for healthcare organizations. The company serves customers in the United States and internationally through direct sales, distribution, key account management, inside sales, and e-commerce. Headquartered in Eagan, Minnesota, Solventum focuses on technologies that support safer, more efficient healthcare delivery.
CEO Mr. Bryan C. Hanson · 20,584 employees · United States · https://www.solventum.com
